Iruxol N (Collagenase Clostridium Histolyticum, Protease)

Iruxol N, an enzymatic debridement agent, is used in wound care to remove necrotic tissue and improve healing.

• Pressure ulcers: facilitates removal of necrotic tissue and promotes granulation tissue formation.
• Diabetic foot ulcers: aids debridement of chronic lesions, supporting faster wound closure.
• Chronic non‑healing wounds: enzymatically clears extracellular matrix debris to improve the wound bed.

• Collagenase Clostridium Histolyticum hydrolyzes native collagen and other extracellular matrix proteins at the wound surface. By breaking down fibrillar collagen, the enzyme loosens necrotic tissue, allowing mechanical removal and exposing viable tissue, which accelerates granulation and re‑epithelialisation in chronic wounds.

Local and systemic reactions may occur with Iruxol N; reported events are categorized by frequency.

Common Side Effects

• Local pain or burning sensation at the application site.
• Redness or erythema around the treated area.
• Swelling or edema of the surrounding skin.
• Mild itching or pruritus.
• Slight bleeding or oozing from the debrided tissue.
• Increased wound drainage.

Serious or Rare Side Effects

• Allergic reaction including anaphylaxis.
• Severe infection of the treated wound.
• Unintended tissue necrosis extending beyond target area.
• Systemic hypersensitivity responses.
• Significant hemorrhage.
• Deep ulceration or perforation.

Iruxol N should be used under professional supervision with attention to wound characteristics and patient safety.

• Assess wound type: ensure the wound contains necrotic tissue suitable for enzymatic debridement.
• Avoid application on healthy or granulating tissue.
• Monitor for signs of infection or excessive pain during treatment.
• Do not combine with other topical proteolytic enzymes unless directed by a clinician.
• Use only as prescribed by a qualified healthcare provider.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Iruxol N may interact with other topical agents or systemic medications that affect coagulation or wound healing.

Major Interactions (Avoid)

• Concurrent use of other proteolytic enzymes, which can amplify tissue breakdown.
• Systemic anticoagulants (e.g., warfarin, heparin) increasing bleeding risk at the application site.
• Topical antibiotics containing oxidizing agents that may inactivate the collagenase.

Moderate Interactions (Monitor Closely)

• Moisturizers or dressings containing zinc oxide or high protein content that could bind the enzyme.
• Radiation therapy applied to the same wound area, potentially altering enzyme activity.
• Use with corticosteroid creams, which may reduce local inflammatory response and affect efficacy.
• Application over areas treated with chemical cautery or laser therapy.